title: Comment on Bordeleau et al. The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. Diabetes Care 2014;37:1360-1366.
authors.affiliation: Comprehensive Cancer Centre The Netherlands, Eindhoven, the Netherlands m.zanders@iknl.nl.
authors.forename: Marjolein M J
authors.initials: MM
authors.lastname: Zanders
authors.affiliation: Institute of Cancer Sciences, University of Manchester, Manchester, U.K.
authors.forename: Andrew G
authors.initials: AG
authors.lastname: Renehan
authors.affiliation: School of Public Health, University of Alberta, Edmonton, Alberta, Canada.
authors.forename: Samantha L
authors.initials: SL
authors.lastname: Bowker
authors.affiliation: Steno Diabetes Center, Gentofte, Denmark.
authors.forename: Bendix
authors.initials: B
authors.lastname: Carstensen
authors.affiliation: Comprehensive Cancer Centre The Netherlands, Eindhoven, the Netherlands.
authors.forename: Lonneke V
authors.initials: LV
authors.lastname: van de Poll-Franse
authors.affiliation: School of Public Health, University of Alberta, Edmonton, Alberta, Canada.
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Johnson
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D049528:Insulin, Long-Acting / Q000008:administration & dosage*; D009369:Neoplasms / Q000209:etiology*
chemical_list: D000970:Antineoplastic Agents; D015525:Fatty Acids, Omega-3; D007004:Hypoglycemic Agents; D049528:Insulin, Long-Acting